CAR T-cell therapy for immune thrombocytopenia and autoimmune hemolytic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new treatment using modified immune cells (CAR T-cells) to target and destroy the faulty cells that attack your blood cells in ITP or wAIHA. It aims to reset your immune system to stop the disease and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic ITP or warm autoimmune hemolytic anemia (wAIHA).
- You have tried at least two prior treatments, including steroids and either TPO agonists (for ITP) or rituximab (for wAIHA), and they have not worked or stopped working.
- Your blood counts and organ function are within acceptable ranges (e.g., adequate white blood cells, kidney and liver function, heart function).
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and after the study.
- You have no active infections, including HIV, hepatitis B or C, or other uncontrolled infections.
- You have not had a previous CAR T-cell treatment or gene therapy.
- Your overall health is good (able to perform daily activities, no major organ damage).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
This trial tests a new type of cell therapy (CAR T cells) that targets and removes specific immune cells causing low platelets. It is for people with immune thrombocytopenia (ITP) that has not improved with standard treatments. The goal is to see if this therapy is safe and can help raise platelet counts.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests a new type of cell therapy called Inaticabtagene Autoleucel (a personalized treatment made from your own immune cells) for people with autoimmune hemolytic anemia that has not improved after three or more prior treatments. The goal is to see if this therapy can stop the immune system from destroying red blood cells and help increase your hemoglobin levels.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
Hear when a new Cytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.